Search results
COVID-19 Vaccines. Updates on COVID-19 Vaccines. Available Vaccines. Current evidence of the COVID-19 vaccines with Emergency Use Authorization (EUA) approvals by Philippine Food and Drug Administration.
Aug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Dec 11, 2020 · The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to: prevent COVID-19 in individuals 12 years of age and older, and. provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise.
Aug 23, 2021 · The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) - Food and Drug Administration. Pfizer-BioNTech/Comirnaty COVID-19 mRNA Vaccine (nucleoside modified) For more information on reporting side effects, click here.
COVID-19. The Pfizer-BioNTech COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is currently no Food and Drug Administration (FDA) Philippines approved vaccine to prevent COVID-19. Read this Fact Sheet for information about the Pfizer-BioNTech COVID-19 Vaccine.
Sep 11, 2023 · The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19.
Sep 22, 2021 · First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain. In trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profile.
Jun 27, 2024 · The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineages Doses will be ready to ship to applicable EU member ...
